RenovoRx annual r&d spending
2020
2021
2022
2023
2024
2025
RenovoRx R&D Spending Growth & History (RNXT)
RenovoRx's r&d spending was $6.3M for fiscal 2025.
View full RenovoRx company overviewRenovoRx annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.3M | $244,000 | +4.05% |
| 2024 | 2024-12-31 | $6.0M | $358,000 | +6.32% |
| 2023 | 2023-12-31 | $5.7M | $1.4M | +31.76% |
| 2022 | 2022-12-31 | $4.3M | $1.3M | +41.53% |
| 2021 | 2021-12-31 | $3.0M | $653,000 | +27.37% |
| 2020 | 2020-12-31 | $2.4M | — | — |
RenovoRx quarterly r&d spending
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.2M | −$226,000 | −15.85% |
| Q1 2026 | 2026-03-31 | $1.2M | −$414,000 | −25.21% |
| Q4 2025 | 2025-12-31 | $1.5M | −$60,000 | −3.81% |
| Q3 2025 | 2025-09-30 | $1.7M | $35,000 | +2.12% |
| Q2 2025 | 2025-06-30 | $1.4M | −$116,000 | −7.52% |
| Q1 2025 | 2025-03-31 | $1.6M | $385,000 | +30.63% |
| Q4 2024 | 2024-12-31 | $1.6M | $801,000 | +103.35% |
| Q3 2024 | 2024-09-30 | $1.6M | $21,000 | +1.29% |
| Q2 2024 | 2024-06-30 | $1.5M | −$383,000 | −19.90% |
| Q1 2024 | 2024-03-31 | $1.3M | −$81,000 | −6.05% |
| Q4 2023 | 2023-12-31 | $775,000 | −$1,000 | −0.13% |
| Q3 2023 | 2023-09-30 | $1.6M | $783,000 | +92.55% |
| Q2 2023 | 2023-06-30 | $1.9M | $535,000 | +38.49% |
| Q1 2023 | 2023-03-31 | $1.3M | $49,000 | +3.80% |
| Q4 2022 | 2022-12-31 | $776,000 | −$325,000 | −29.52% |
| Q3 2022 | 2022-09-30 | $846,000 | $79,000 | +10.30% |
| Q2 2022 | 2022-06-30 | $1.4M | $854,000 | +159.33% |
| Q1 2022 | 2022-03-31 | $1.3M | $654,000 | +102.99% |
| Q4 2021 | 2021-12-31 | $1.1M | — | — |
| Q3 2021 | 2021-09-30 | $767,000 | $40,000 | +5.50% |
| Q2 2021 | 2021-06-30 | $536,000 | — | — |
| Q1 2021 | 2021-03-31 | $635,000 | — | — |
| Q3 2020 | 2020-09-30 | $727,000 | — | — |
RenovoRx r&d spending trends
Over the last five fiscal years, RenovoRx's r&d spending increased from $2.4M to $6.3M, a change of $3.9M. The latest reported quarter, Q2 2026, shows $1.2M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review RenovoRx source filings ↗